Fig. 1

Talazoparib and decitabine synergize in treatment of M231^wt and isogenic BRCA1 and BRCA2-targeted mutants. A M231 cells with targeted mutations in the BRCA1 or BRCA2 loci do not assemble significant numbers of RAD51 foci in response to 16-h treatment with 8 uM carboplatin. M231^wt, M231 cells with intact HRR genes; M231^BRCA1, cells with targeted mutations in BRCA1; M231^BRCA2, cells with targeted mutations in BRCA2 mean ± SEM calculated and significance determined by two-way ANOVA with Tukey’s adjustment for multiple testing. B–E Drug effects on final population sizes measured by SRB assay at day 6 of culture, means ± SD calculated and significance determined via 1-way ANOVA with Tukey’s adjustment for multiple testing. F–I Cell cycle profiles at 48 h of drug treatment as indicated. B–I Drugs: Deci,14 nM decitabine; Tala, 5 nM talazoparib; or 14 nM Deci + 5 nM Tala; or DMSO. A–I All experiments used at least triplicate samples, and were performed at least twice. ****, p < 0.0001; ***, p < 0.001; **, p < 0.01; ns, not significant